U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
South Korean biopharmaceutical firm Celltrion Inc. will acquire the patent, trademark, and sales rights for 18 brands of Japan's Takeda Pharmaceutical in Asia-Pacific for 332.4 billion won.
The company will pursue the deal through its Singapore-based affiliate, hoping the complete the acquisition by year's end.
The nine markets covered by business rights include South Korea, Thailand, Malaysia, and Australia.
The 18 brands amassed a combined sales of $140 million in Asia-Pacific in 2018.
Celltrion plans to sell the brands through its affiliates Celltrion Pharma and Celltrion Healthcare.
The acquisition not only helps to stabilize the local supply of medication for hypertension, diabetes, and hyperlipidemia but also serves as Celltrion's first significant move in accelerating its push into the global market.
Celltrion had a net income of 298 billion won in 2019, a 17.5 percent surge from the year before.
